The guidelines issued by the Department of Health and Human Services (HHS) have been updated with recent, evidence-based consensus of The Panel for the Use of Antiretroviral Agents in Adults and Adolescents.
|Videos|March 19, 2018
What Can Be Done to Get More Individuals Tested for HIV?
Author(s)Contagion® Editorial Staff
Colleen Kelley, MD, explains what is needed to ensure that individuals get tested for HIV.
Advertisement
Colleen Kelley, MD, associate professor of medicine for the Division of Infectious Diseases in the department of Medicine at Emory University School of Medicine, discusses what is needed to ensure that all individuals get tested for HIV—not just those who are at elevated risk. Dr. Kelley stresses that public health campaigns can be instrumental in raising awareness as well as increasing availability and accessibility to testing. As a medical community, she feels that HIV testing needs to be routinized; everyone between the ages of 15 and 64 should get tested at least once in their lifetime according to public health guidelines.
Advertisement
Related to this article
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.
Pritelivir (Hovilpri) healed all lesions by day 28 in 63% of immunocompromised adults with refractory HSV versus 34% with investigator's choice in the phase 3 PRIOH-1 trial.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Advertisement
Advertisement
Trending on Contagion Live
1
Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
4
Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events
5